An open-label, single-dose study to evaluate the pharmacokinetics and safety of MDV3100 in healthy Chinese male volunteers
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Enzalutamide (Primary)
- Indications Bladder cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Salivary gland cancer
- Focus Pharmacokinetics
- Sponsors Astellas Pharma China
- 11 Jan 2019 Results published in the Clinical Therapeutics
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 New trial record